BioNTech’s (BNTX) Outperform Rating Reaffirmed at BMO Capital Markets

BioNTech (NASDAQ:BNTX)‘s stock had its “outperform” rating reissued by equities researchers at BMO Capital Markets in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports.

A number of other brokerages have also recently commented on BNTX. UBS Group lifted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. TD Cowen reduced their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Finally, Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Price Performance

BNTX stock traded down $0.20 during trading on Monday, hitting $118.19. 51,004 shares of the stock traded hands, compared to its average volume of 812,466. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market cap of $28.33 billion, a price-to-earnings ratio of -56.64 and a beta of 0.26. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a 50 day simple moving average of $113.81 and a 200 day simple moving average of $98.73.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue was up 38.9% on a year-over-year basis. During the same period last year, the firm posted $0.73 EPS. Equities analysts expect that BioNTech will post -3.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC lifted its position in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after acquiring an additional 238 shares during the period. EverSource Wealth Advisors LLC increased its holdings in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Planning Capital Management Corp increased its holdings in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the period. Blue Trust Inc. lifted its holdings in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the period. Finally, Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.